Infectious disease
The WHO’s Emergency Use Listing (EUL), a prerequisite for COVAX Facility vaccine supply, evaluates the safety, quality, and efficacy of the COVID-19 vaccines. As such, today’s approval allows the vaccine to be used by agencies and NGOs around the world.
Early results from University of Oxford’s RECOVERY trial showed Roche’s immunosuppressant Actemra reduced deaths and the need for mechanical ventilation in severe COVID patients.
It was a busy week for clinical trial announcements and news. Here’s a look.
With billions invested in R&D over the past year to find vaccines and therapies for the novel coronavirus, a few select life sciences companies and academic institutions are working on the hypothesis that intranasal vaccines and therapies could be key to stopping COVID-19 in its tracks, and provide greater protection against transmission of COVID-19.
An observational study published in the Proceedings of the National Academy of Sciences suggests there is a strong positive association between the number of coronavirus disease 2019 (COVID-19) aerosol droplets an individual breathes out with age, infection and body weight.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
There are some big surprises among the list of major players in the vaccine space who either dropped their programs or have been significantly delayed.
The origins of COVID-19 continue to be debated in the halls of government, and the findings from a recent investigation conducted by the World Health Organization are unlikely to change many minds as the world continues to grapple with the pandemic.
South Africa recently announced it was halting distribution of the AstraZeneca-University of Oxford COVID-19 vaccine after data suggested it “provides minimal protection” against mild disease from the South African variant.
This combination therapy has been authorized for the treatment of mild to moderate COVID-19 in patients aged 12 and older who are at high risk for progressing to severe COVID-19 and/or hospitalization.
PRESS RELEASES